These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 18783301

  • 1. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
    Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Clin Drug Investig; 2008; 28(10):625-34. PubMed ID: 18783301
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [Abstract] [Full Text] [Related]

  • 3. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Atherosclerosis; 2009 May 01; 204(1):208-15. PubMed ID: 18996523
    [Abstract] [Full Text] [Related]

  • 5. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.
    Vasc Health Risk Manag; 2013 May 01; 9():719-27. PubMed ID: 24265554
    [Abstract] [Full Text] [Related]

  • 6. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.
    Clin Drug Investig; 2010 May 01; 30(1):51-61. PubMed ID: 19995098
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
    Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC.
    Cardiovasc Drugs Ther; 2011 Feb 01; 25(1):59-67. PubMed ID: 21416219
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.
    Clin Ther; 2013 Aug 01; 35(8):1186-98. PubMed ID: 23891363
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2010 Dec 01; 24(5-6):421-8. PubMed ID: 20953684
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Dec 01; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 01; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2011 Feb 01; 25(1):47-57. PubMed ID: 21174145
    [Abstract] [Full Text] [Related]

  • 16. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC.
    Arterioscler Thromb Vasc Biol; 2014 Jun 01; 34(6):1298-306. PubMed ID: 24743431
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hyperlipidaemia with fenofibrate and related fibrates.
    Filippatos T, Milionis HJ.
    Expert Opin Investig Drugs; 2008 Oct 01; 17(10):1599-614. PubMed ID: 18808320
    [Abstract] [Full Text] [Related]

  • 18. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
    Filippatos TD.
    Cardiovasc Drugs Ther; 2012 Jun 01; 26(3):245-55. PubMed ID: 22592524
    [Abstract] [Full Text] [Related]

  • 19. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE.
    JAMA; 2011 Nov 16; 306(19):2099-109. PubMed ID: 22089718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.